CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Niraparib Pilldrug
Likely dose
Niraparib Pill 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04288687
NCT04288687Phase 2Completed
CompareCT.gov

PLATPARP: A Phase II Single-Arm Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Abramson Cancer Center at Penn Medicine·interventional·Posted Feb 28, 2020·Updated Mar 4, 2026

In Brief

A Phase 2 clinical trial evaluating Niraparib Pill for Prostate Adenocarcinoma. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This study is designed to evaluate the initial safety and effectiveness of an investigational drug, niraparib, given to patients who have recently received platinum-based chemotherapy for the treatment of prostate cancer. The study enrolls participants with history of advanced prostate cancer that is growing despite standard hormonal therapies, such as androgen-deprivation therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Adenocarcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 28, 2020
Enrollment StartOct 19, 2020
Primary CompletionFeb 20, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.3 years ago

Interventions

Niraparib Pilldrug

Niraparib 200 mg by mouth daily (2 x 100 mg pills)